{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T18:20:14Z","timestamp":1786990814587,"version":"build-2736575974"},"reference-count":36,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2019,5,1]],"date-time":"2019-05-01T00:00:00Z","timestamp":1556668800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"China Health Promotion Foundation","award":["THC2015001"],"award-info":[{"award-number":["THC2015001"]}]},{"name":"Youth Fund of Changhai Hospital","award":["CH201709"],"award-info":[{"award-number":["CH201709"]}]}],"content-domain":{"domain":["redjournal.org","clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Radiation Oncology*Biology*Physics"],"published-print":{"date-parts":[[2019,5]]},"DOI":"10.1016\/j.ijrobp.2019.01.075","type":"journal-article","created":{"date-parts":[[2019,1,25]],"date-time":"2019-01-25T04:37:31Z","timestamp":1548391051000},"page":"101-110","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":80,"title":["Patterns of Local Failure After Stereotactic Body Radiation Therapy and Sequential Chemotherapy as Initial Treatment for Pancreatic Cancer: Implications of Target Volume Design"],"prefix":"10.1016","volume":"104","author":[{"given":"Xiaofei","family":"Zhu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoping","family":"Ju","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yangsen","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuxin","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fei","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuiwang","family":"Qing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fang","family":"Fang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhen","family":"Jia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huojun","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijrobp.2019.01.075_bib1","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3322\/caac.21442","article-title":"Cancer statistics, 2018","volume":"68","author":"Siegel","year":"2018","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.ijrobp.2019.01.075_bib2","doi-asserted-by":"crossref","first-page":"115","DOI":"10.3322\/caac.21338","article-title":"Cancer statistics in China, 2015","volume":"66","author":"Chen","year":"2016","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.ijrobp.2019.01.075_bib3","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S1072-7515(99)00075-7","article-title":"Pancreatic cancer: A report of treatment and survival trends for 100,313 patients diagnosed from 1985-1995 using the national cancer database","volume":"189","author":"Sener","year":"1999","journal-title":"J Am Coll Surg"},{"key":"10.1016\/j.ijrobp.2019.01.075_bib4","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1586\/14737140.2016.1168698","article-title":"Stereotactic body radiotherapy for pancreatic cancer: Recent progress and future directions","volume":"16","author":"Myrehaug","year":"2016","journal-title":"Expert Rev Anticancer Ther"},{"key":"10.1016\/j.ijrobp.2019.01.075_bib5","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1097\/COC.0b013e3181d270b4","article-title":"Stereotactic body radiotherapy in the treatment of advanced adenocarcinoma of the pancreas","volume":"34","author":"Rwigema","year":"2011","journal-title":"Am J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2019.01.075_bib6","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/j.ijrobp.2009.08.046","article-title":"Stereotactic body radiotherapy and gemcitabine for locally advanced pancreatic cancer","volume":"78","author":"Mahadevan","year":"2010","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2019.01.075_bib7","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1016\/j.ijrobp.2013.02.022","article-title":"Stereotactic body radiation therapy for locally advanced and borderline resectable pancreatic cancer is effective and well tolerated","volume":"86","author":"Chuong","year":"2013","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2019.01.075_bib8","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1177\/1533034616650778","article-title":"Can stereotactic body radiation therapy be a viable and efficient therapeutic option for unresectable locally advanced pancreatic adenocarcinoma? Results of a phase 2 study","volume":"16","author":"Comito","year":"2017","journal-title":"Technol Cancer Res Treat"},{"key":"10.1016\/j.ijrobp.2019.01.075_bib9","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1016\/j.ijrobp.2012.01.022","article-title":"Radiation Therapy Oncology Group consensus panel guidelines for the delineation of the clinical target volume in the postoperative treatment of pancreatic head cancer","volume":"83","author":"Goodman","year":"2012","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2019.01.075_bib10","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1016\/j.ijrobp.2013.09.005","article-title":"Mapping patterns of local recurrence after pancreaticoduodenectomy for pancreatic adenocarcinoma: A new approach to adjuvant radiation field design","volume":"87","author":"Dholakia","year":"2013","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2019.01.075_bib11","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ijrobp.2019.01.075_bib12","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1148\/radiol.2018171670","article-title":"Pancreatic adenocarcinoma staging in the era of preoperative chemotherapy and radiation therapy","volume":"287","author":"Zins","year":"2018","journal-title":"Radiology"},{"key":"10.1016\/j.ijrobp.2019.01.075_bib13","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1159\/000086771","article-title":"An early phase II study of S-1 in patients with metastatic pancreatic cancer","volume":"68","author":"Hartmann","year":"2005","journal-title":"Oncology"},{"key":"10.1016\/j.ijrobp.2019.01.075_bib14","doi-asserted-by":"crossref","first-page":"1640","DOI":"10.1200\/JCO.2012.43.3680","article-title":"Randomized phase III study of gemcitabine plus S-1, S-1 alone, or gemcitabine alone in patients with locally advanced and metastatic pancreatic cancer in Japan and Taiwan: GEST study","volume":"31","author":"Ueno","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2019.01.075_bib15","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1007\/s00280-008-0741-7","article-title":"A phase II study of S-1 in gemcitabine-refractory metastatic pancreatic cancer","volume":"63","author":"Morizane","year":"2009","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.ijrobp.2019.01.075_bib16","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1007\/s00280-010-1311-3","article-title":"Phase II study of S-1 in patients with gemcitabine-resistant advanced pancreatic cancer","volume":"67","author":"Sudo","year":"2011","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.ijrobp.2019.01.075_bib17","doi-asserted-by":"crossref","first-page":"2263","DOI":"10.1002\/cam4.1164","article-title":"Prognostic role of stereotactic body radiation therapy for elderly patients with advanced and medically inoperable pancreatic cancer","volume":"6","author":"Zhu","year":"2017","journal-title":"Cancer Med"},{"key":"10.1016\/j.ijrobp.2019.01.075_bib18","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/j.radonc.2018.08.012","article-title":"Prediction of overall survival after re-irradiation with stereotactic body radiation therapy for pancreatic cancer with a novel prognostic model (the SCAD score)","volume":"129","author":"Zhu","year":"2018","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.ijrobp.2019.01.075_bib19","doi-asserted-by":"crossref","first-page":"4805","DOI":"10.2147\/CMAR.S166713","article-title":"Health-related quality of life for gemcitabine and nab-paclitaxel plus radiotherapy versus gemcitabine and S-1 plus radiotherapy in patients with metastatic pancreatic cancer","volume":"10","author":"Zhu","year":"2018","journal-title":"Cancer Manag Res"},{"key":"10.1016\/j.ijrobp.2019.01.075_bib20","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.2147\/CMAR.S163655","article-title":"Stereotactic body radiation therapy plus induction or adjuvant chemotherapy for early stage but medically inoperable pancreatic cancer: A propensity score-matched analysis of a prospectively collected database","volume":"10","author":"Zhu","year":"2018","journal-title":"Cancer Manag Res"},{"key":"10.1016\/j.ijrobp.2019.01.075_bib21","doi-asserted-by":"crossref","first-page":"4078","DOI":"10.1118\/1.3438081","article-title":"Stereotactic body radiation therapy: The report of AAPM Task Group 101","volume":"37","author":"Benedict","year":"2010","journal-title":"Med Phys"},{"key":"10.1016\/j.ijrobp.2019.01.075_bib22","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.radonc.2010.08.020","article-title":"Patterns of failure and comparison of different target volume delineations in patients with glioblastoma treated with conformal radiotherapy plus concomitant and adjuvant temozolomide","volume":"97","author":"Minniti","year":"2010","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.ijrobp.2019.01.075_bib23","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/S0360-3016(98)00266-1","article-title":"Patterns of failure following high-dose 3-D conformal radiotherapy for high-grade astrocytomas: A quantitative dosimetric study","volume":"43","author":"Lee","year":"1999","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2019.01.075_bib24","doi-asserted-by":"crossref","first-page":"2158","DOI":"10.1002\/cncr.30057","article-title":"A novel systemic inflammation response index (SIRI) for predicting the survival of patients with pancreatic cancer after chemotherapy","volume":"122","author":"Qi","year":"2016","journal-title":"Cancer"},{"key":"10.1016\/j.ijrobp.2019.01.075_bib25","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1080\/01635581.2016.1250921","article-title":"The significance of the prognostic nutritional index for all stages of pancreatic cancer","volume":"69","author":"Lee","year":"2017","journal-title":"Nutr Cancer"},{"key":"10.1016\/j.ijrobp.2019.01.075_bib26","doi-asserted-by":"crossref","first-page":"1508","DOI":"10.1016\/j.ejso.2015.07.022","article-title":"Prognostic nutritional index predicts survival and correlates with systemic inflammatory response in advanced pancreatic cancer","volume":"41","author":"Geng","year":"2015","journal-title":"Eur J Surg Oncol"},{"key":"10.1016\/j.ijrobp.2019.01.075_bib27","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1016\/0895-4356(94)90129-5","article-title":"Validation of a combined comorbidity index","volume":"47","author":"Charlson","year":"1994","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.ijrobp.2019.01.075_bib28","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1016\/j.surg.2014.12.006","article-title":"Fern\u00e1ndez-Del Castillo C. The Charlson age comorbidity index predicts early mortality after surgery for pancreatic cancer","volume":"157","author":"Dias-Santos","year":"2015","journal-title":"Surgery"},{"key":"10.1016\/j.ijrobp.2019.01.075_bib29","doi-asserted-by":"crossref","first-page":"2897","DOI":"10.1200\/JCO.2005.05.3934","article-title":"Perioperative CA19-9 levels can predict stage and survival in patients with resectable pancreatic adenocarcinoma","volume":"24","author":"Ferrone","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2019.01.075_bib30","doi-asserted-by":"crossref","first-page":"4548","DOI":"10.1200\/JCO.2011.36.5742","article-title":"Gemcitabine plus nab-paclitaxel is an active regimen in patients with advanced pancreatic cancer: A phase I\/II trial","volume":"29","author":"Von Hoff","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2019.01.075_bib31","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1001\/jamasurg.2017.2227","article-title":"Association of clinical factors with a major pathologic response following preoperative therapy for pancreatic ductal adenocarcinoma","volume":"152","author":"Cloyd","year":"2017","journal-title":"JAMA Surg"},{"key":"10.1016\/j.ijrobp.2019.01.075_bib32","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1016\/j.ijrobp.2014.02.031","article-title":"Baseline metabolic tumor volume and total lesion glycolysis are associated with survival outcomes in patients with locally advanced pancreatic cancer receiving stereotactic body radiation therapy","volume":"89","author":"Dholakia","year":"2014","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2019.01.075_bib33","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1016\/j.radonc.2016.12.030","article-title":"Dosimetric parameters correlate with duodenal histopathologic damage after stereotactic body radiotherapy for pancreatic cancer: Secondary analysis of a prospective clinical trial","volume":"122","author":"Verma","year":"2017","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.ijrobp.2019.01.075_bib34","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1186\/s13014-016-0714-7","article-title":"Pancreatic cancer adjuvant radiotherapy target volume design: Based on the postoperative local recurrence spatial location","volume":"11","author":"Yu","year":"2016","journal-title":"Radiat Oncol"},{"key":"10.1016\/j.ijrobp.2019.01.075_bib35","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1016\/j.ijrobp.2015.12.003","article-title":"Focal radiation therapy dose escalation improves overall survival in locally advanced pancreatic cancer patients receiving induction chemotherapy and consolidative chemoradiation","volume":"94","author":"Krishnan","year":"2016","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2019.01.075_bib36","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1097\/COC.0000000000000472","article-title":"Dose escalation in stereotactic body radiation therapy for pancreatic cancer: A meta-analysis","volume":"42","author":"Zaorsky","year":"2019","journal-title":"Am J Clin Oncol"}],"container-title":["International Journal of Radiation Oncology*Biology*Physics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0360301619301579?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0360301619301579?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,11,11]],"date-time":"2019-11-11T16:26:27Z","timestamp":1573489587000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0360301619301579"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,5]]},"references-count":36,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,5]]}},"alternative-id":["S0360301619301579"],"URL":"https:\/\/doi.org\/10.1016\/j.ijrobp.2019.01.075","relation":{},"ISSN":["0360-3016"],"issn-type":[{"value":"0360-3016","type":"print"}],"subject":[],"published":{"date-parts":[[2019,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Patterns of Local Failure After Stereotactic Body Radiation Therapy and Sequential Chemotherapy as Initial Treatment for Pancreatic Cancer: Implications of Target Volume Design","name":"articletitle","label":"Article Title"},{"value":"International Journal of Radiation Oncology*Biology*Physics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijrobp.2019.01.075","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}